Recro Pharma, an oral solid dose contract development and manufacturing organization (CDMO), has made several appointments to its management team and board of directors.  Recro named Jim Miller, a highly regarded CDMO industry thought leader, to its board of directors. Additionally, the company appointed Ryan Lake, who has more than 20 years of senior financial and life sciences experience, as chief financial officer, in late 2020.  These additions, along with the appointment of David Enloe as chief executive officer in late 2020, highlight the company’s ongoing commitment to build a world-class leadership team of experienced CDMO industry veterans best positioned to drive significant growth for Recro’s differentiated business within the rapidly expanding manufacturing services market.
 
“These latest appointments are key milestones for Recro not only in terms of the quality of individuals they involve but also for what they represent in terms of the company’s laser focus on building the right team for leading Recro to success in the fast growing CDMO space,” said Mr. Enloe.  “While Recro has a long and successful track record of solving complex drug formulation, delivery and manufacturing challenges for oral, solid dose drug products, the company has traditionally been an organization largely focused on its own product pipeline.  We believe that the recent enhancements to the company’s management and board, including the appointments of Jim and Ryan, further position Recro with the right leadership team to maximize the company’s shift to an externally facing organization, and to transition its world-class end-to-end CDMO expertise and capabilities into a rapidly growing business.”
 
Mr. Miller is a well-known and highly regarded advisor on drug manufacturing strategy and a pre-eminent authority on the biopharmaceutical CDMO industry. He is founder and former president of PharmSource, the CDMO industry’s principal source of market intelligence, which was sold to Global Data, a London-based, publicly-traded provider of market intelligence services in 2016. Throughout his career, Mr. Miller has advised most major CDMOs on business strategy, major capital investment decisions and acquisitions, and served on due diligence teams for high profile acquisitions made by private equity firms. Most recently, he has served on the advisory boards of Ajinomoto Biopharma Services, a leading CDMO with large and small molecule manufacturing operations around the world, and C-Squared Pharma, a Luxembourg-based generic active pharmaceutical ingredient (API) supplier.
  
Upon his appointment as chief executive in late 2020, Mr. Enloe selected Mr. Lake to serve as dedicated CFO of Recro. Mr. Lake has been part of the legacy Recro Pharma leadership team, joining in 2017 as senior vice president of finance and chief accounting officer and being promoted to CFO in 2018. He played an instrumental role in the spin-off of the therapeutic pipeline development arm of Recro into Baudax Bio in November 2019. Prior to joining Recro, Mr. Lake served as CFO and vice president of finance of Aspire Bariatrics, Inc., a privately-held, commercial-stage, medical device company.